跳至主要内容
临床试验/NCT02357693
NCT02357693已完成4 期

Effect of the Association of Neurokinin-1 Receptor Antagonist Aprepitant to Dexamethasone/Ondansetron in the Incidence of Postoperative Nausea and Vomiting in High Risk Apfel Score Patients

Instituto do Cancer do Estado de São Paulo1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2015年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
90
试验地点
1
主要终点
Incidence of nausea and vomiting in postoperative period

研究概览

简要总结

The purpose of this study is to determine whether patients at high risk for postoperative nausea and vomiting can benefit from aprepitant, ondansetron and dexamethasone in the perioperative period.

详细描述

High risk surgical patients for PONV, scheduled for laparoscopic surgery will be distributed in two groups: Group I will receive aprepitant 80 mg per os and Group II will receive placebo per os, one hour before surgery. In the operating room, patients will be submitted to combined intravenous general anesthesia plus spinal anesthesia. All patients will receive dexamethasone 4 mg and ondansetron 4 mg intravenously during the surgical procedure. After surgery, patients will be monitored for pain, nausea and vomiting during 24 hours.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Care Provider)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • high risk patients for nausea and vomiting

排除标准

  • cardiovascular disease, or hypersensibility to any of the drugs involved in the study

研究组 & 干预措施

aprepitant

Experimental

aprepitant 80 mg one hour before surgery

干预措施: Aprepitant (Drug)

placebo

Placebo Comparator

oral placebo one hour before surgery

干预措施: Aprepitant (Drug)

结局指标

主要结局

Incidence of nausea and vomiting in postoperative period

时间窗: 24 hours

次要结局

未报告次要终点

研究者

发起方
Instituto do Cancer do Estado de São Paulo
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验